Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
August 8, 2025 7:10 AM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,135.00 price target on Eli Lilly (NYSE: LLY)
The analyst comments "We believe we are at an inflection point for "The Broadening" of GLP-1 use, which will extend beyond US-based early adopters to... More
